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Objectives The EVEREST II (Endovascular Valve Edge-to-Edge Repair) High Risk Study (HRS) assessed the safety and effec-
tiveness of the MitraClip device (Abbott Vascular, Santa Clara, California) in patients with significant mitral regur-
gitation (MR) at high risk of surgical mortality rate.
Background Patients with severe MR (3 to 4) at high risk of surgery may benefit from percutaneous mitral leaflet repair, a
potentially safer approach to reduce MR.
Methods Patients with severe symptomatic MR and an estimated surgical mortality rate of 12% were enrolled. A com-
parator group of patients screened concurrently but not enrolled were identified retrospectively and consented to
compare survival in patients treated by standard care.
Results Seventy-eight patients underwent the MitraClip procedure. Their mean age was 77 years, 50% had previous cardiac
surgery, and 46 had functional MR and 32 degenerative MR. MitraClip devices were successfully placed in 96% of
patients. Protocol-predicted surgical mortality rate in the HRS and concurrent comparator group was 18.2% and
17.4%, respectively, and Society of Thoracic Surgeons calculator estimated mortality rate was 14.2% and 14.9%, re-
spectively. The 30-day procedure-related mortality rate was 7.7% in the HRS and 8.3% in the comparator group (p 
NS). The 12-month survival rate was 76% in the HRS and 55% in the concurrent comparator group (p  0.047). In
surviving patients with matched baseline and 12-month data, 78% had an MR grade of 2. Left ventricular end-
diastolic volume improved from 172 ml to 140 ml and end-systolic volume improved from 82 ml to 73 ml (both p 
0.001). New York Heart Association functional class improved from III/IV at baseline in 89% to class I/II in 74% (p 
0.0001). Quality of life was improved (Short Form-36 physical component score increased from 32.1 to 36.1 [p 
0.014] and the mental component score from 45.5 to 48.7 [p  0.065]) at 12 months. The annual rate of hospital-
ization for congestive heart failure in surviving patients with matched data decreased from 0.59 to 0.32 (p  0.034).
Conclusions The MitraClip device reduced MR in a majority of patients deemed at high risk of surgery, resulting in improve-
ment in clinical symptoms and significant left ventricular reverse remodeling over 12 months. (Pivotal Study of a
Percutaneous Mitral Valve Repair System [EVEREST II]; NCT00209274) (J Am Coll Cardiol 2012;59:130–9)
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January 10, 2012:130–9 The EVEREST II HRS: 12-Month ResultsSurgical mitral valve (MV) repair/replacement is currently
the gold standard for treatment of symptomatic patients
with severe (3 to 4) mitral regurgitation (MR) (1–3).
Surgical correction of MR results in improvement in symp-
toms and prolongation of survival in appropriately selected
patients. However, there is a significant number of patients
with symptomatic MR and extensive comorbidities that put
them at high risk of surgical morbidity and mortality rates.
If the surgical risk is judged to be prohibitive, then the
patient may be relegated to medical management only. Some
See page 140
reports suggest that as many as one-half of patients with
symptoms and severe MR may not receive surgery (4).
Patients are currently denied surgical treatment for multiple
reasons, including previous bypass surgery, porcelain aorta,
post-radiation mediastinum, liver disease, renal disease,
significant left ventricular (LV) dysfunction, advanced age,
and other comorbidities (5).
The EVEREST (Endovascular Valve Edge-to-Edge Re-
pair Study) II clinical study was designed to assess the safety
and effectiveness of the MitraClip device (Abbott Vascular,
Santa Clara, California) in treating patients with significant
MR. The High Risk Study (HRS), an arm of the EVER-
EST II trial, enrolled symptomatic patients with 3 to 4
R for whom surgical risk for perioperative mortality rate
as estimated to be 12%, using either the Society of
horacic Surgeons (STS) calculator (6,7) or surgeon co-
nvestigator estimated mortality risk of at least 12% based on
respecified criteria (described in the Methods section).
fter assessment with transthoracic echocardiography
TTE) and transesophageal echocardiography (TEE) to
stablish protocol-based eligibility for the MitraClip proce-
ure (8–11), patients were entered into a prospective,
ulticenter, single-arm study to determine the safety and
ffectiveness of treatment with the MitraClip device. A
roup of patients who were screened for the HRS but were
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accepted August 6, 2011.ot enrolled for various reasons
ere consented retrospectively to
etermine 30-day and 1-year
urvival in patients with similar
egrees of MR, risks, and co-
orbidities treated by standard
f care.
ethods
atient selection. For inclu-
ion, patients had to be symp-
omatic with grade 3 to 4
R and a predicted surgical
ortality risk of 12%, based on
ither the STS risk calculator or
urgeon co-investigator esti-
ated mortality risk following
respecified protocol criteria.
otentially qualifying criteria in-
luded high-risk patients with por-
elain aorta, mobile ascending aorta
theroma, post-mediastinal radia-
ion, functional MR with left ven-
ricular ejection fraction (LVEF)
40%, age older than 75 years
ith LVEF 40%, previous me-
ian sternotomy with patent by-
ass graft(s), 2 previous chest
urgeries, hepatic cirrhosis, or
3 of the following STS high-risk criteria: creatinine level
2.5 mg/dl, previous chest surgery, age older than 75 years,
r LVEF 35%.
We used TTE and TEE screening echocardiograms to
etermine patient eligibility and assessed MR severity and
et origin by TTE. The primary regurgitant jet had to
riginate from leaflet malcoaptation at the A2/P2 region
12). TEE was used to assess MV leaflet anatomy and
orroborate MR jet origin.
We excluded patients if they had evidence of an acute
yocardial infarction within 2 weeks; if they had an
VEF 20% and/or a LV end-systolic dimension 60
m; an MV area 4.0 cm2; leaflet anatomy that might
preclude successful device implantation; a history of MV
leaflet surgery; echocardiographic evidence of an intra-
cardiac mass, thrombus, or vegetation; or active endocar-
ditis. If the patient met all inclusion and no exclusion
criteria, the MitraClip procedure was explained to the
patient as well as the options for continued medical
management and high-risk MV surgery. Patients signed
informed consent and were enrolled in the study. The
U.S. Food and Drug Administration approved the study
protocol, and the informed consent document was reviewed
and approved by the institutional review boards at the partic-
Abbreviations
and Acronyms
CHF  congestive heart
failure
DMR  degenerative mitral
regurgitation with abnormal
structure of at least 1
mitral valve leaflet
ECL  echocardiography
core laboratory
FMR  mitral regurgitation
with normal structure of
both mitral valve leaflets
HRS  High Risk Study
LV  left ventricular
LVEF  left ventricular
ejection fraction
NYHA  New York Heart
Association
MAE  major adverse
event(s)
MR  mitral regurgitation
MV  mitral valve
STS  Society of Thoracic
Surgery
TEE  transesophageal
echocardiography
TTE  transthoracic
echocardiographyipating institutions.
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The EVEREST II HRS: 12-Month Results January 10, 2012:130–9After enrollment in the trial, the patient’s MR was graded
by a central independent echocardiographic core laboratory
(ECL) (University of California, San Francisco) at baseline
and all follow-up visits using the American Society of
Echocardiography criteria (13,14). Major adverse events
(MAEs) through 12 months were adjudicated by a central
events committee (Harvard Clinical Research Institute).
Cause of death in the HRS was adjudicated by the central
events committee as cardiac or noncardiac related. Cause of
death in the concurrent comparator group was site reported
as cardiac or noncardiac.
Concurrently screened comparator group. We retrospec-
tively (after results of the HRS were known) identified 58
patients with MR severity of 3 and a predicted surgical
mortality rate of 12% screened for enrollment in the HRS
who did not enroll or were not anatomically eligible for
MitraClip device placement. Twenty-two patients were not
included in the concurrent comparator group due to lack of
site institutional review board approval to include patients in
the comparator group (n  11), lack of patient informed
consent (n  5), or inability to contact the patient (n  6).
atients were requested to participate in the study by
onsenting to 1-year follow-up to determine survival. Base-
ine transthoracic echocardiograms were assessed for MR
everity by the site echocardiologist. Baseline LVEF, LV
nd-systolic dimension, and anatomic assessment for the
bility to place a MitraClip device was performed by a
entral team of echocardiographers who were trained by the
CL and under contract with the sponsor. Twenty-two
ercent (n  8) of the comparator group met all HRS
ligibility criteria but were not enrolled in the HRS because
tudy enrollment had ended or they elected to not enroll.
ineteen percent (n  7) of the comparator group were
etermined to be eligible based on transthoracic echocar-
iographic assessment of MR severity; however, anatomic
ligibility based on a transthoracic echocardiogram was
ever confirmed. The other 58% of patients (n  21)
ncluded in the comparator group met all eligibility criteria
xcept for 1 or more specific anatomic protocol criteria
elated to MitraClip device placement (10). Anatomic
xclusions included MV area 4.0 cm2 (n  4), jet origin
ther than A2-P2 (n  4), flail width of 15 mm, or flail
gap of 10 mm (n  2), coaptation length of 2 mm (n 
3), leaflet calcification (n  7), or a severely retracted
posterior leaflet (n 1). All comparator group patients were
treated according to standard of care over the 12-month
period, with 86% managed medically and 14% undergo-
ing MV surgery. The date of screening for these patients
was considered time zero to determine the natural history
of MR treated by standard of care and mortality rate
associated with significant MR. Survival at 30 days and at
1 year in the concurrent comparator group was compared
with that of the HRS patients treated with the MitraClip
device.
MitraClip procedure. The MitraClip procedure was per-
formed with the patient under general anesthesia usingTEE and fluoroscopic guidance in the cardiac catheteriza-
tion laboratory, as previously described (8–11). After trans-
septal puncture, heparin was administered. The transseptal
sheath was exchanged for the steerable guide catheter and
dilator. The MitraClip Delivery System was introduced into
the steerable guide catheter, and the MitraClip device was
advanced into the left atrium. The MitraClip device was
then steered and positioned until axially aligned and
centered over the origin of the regurgitant jet. The
MitraClip device arms were opened, and it advanced into
the left ventricle below the mitral leaflets. The MitraClip
device was then retracted until both leaflets were grasped
and closed to coapt the mitral leaflets across the regur-
gitant orifice. Leaflet insertion into the MitraClip device
and MR reduction were assessed using 2-dimensional
and Doppler echocardiography. If necessary, the device
was reopened, the leaflets released, and the MitraClip
device repositioned. If the MitraClip device needed to be
withdrawn into the left atrium, the arms were inverted in
the ventricle, providing a profile for easy retraction into
the atrium. After adequate reduction of MR was achieved
after a hemodynamic challenge, the MitraClip device was
deployed, and the catheters were withdrawn. A second
MitraClip device was placed at operator discretion to
obtain additional MR reduction. Patients were treated
with aspirin 325 mg/day for 6 months and clopidogrel 75
mg for 30 days (10,11).
TTE was performed at baseline, before hospital dis-
charge, at 30 days, 6 months, and 12 months after Mitra-
Clip device placement according to protocol, and the
transthoracic echocardiograms were sent to the independent
ECL for analysis.
Statistical analysis. Data were analyzed by intention to
treat unless otherwise specified. Serial matched data are
shown for surviving patients only. Continuous data are
expressed as mean  SD and are compared with either a
paired or independent Student t test. Categorical data are
expressed as a percentage and compared using the Fisher
exact test, and ordinal data are expressed as a percentage and
compared using the Bowker test. For estimation of surgical
risk, either the number calculated from the STS calculator
was used if 12% or the surgeon’s estimated mortality rate
was used if the calculated STS score was 12%. Data using
the STS calculator score only are also shown. A Clopper-
Pearson exact binomial method was used to determine
whether the observed 30-day mortality rate was lower than
the 1-sided 95.472% upper confidence limit of the esti-
mated 30-day mortality rate. The Kaplan-Meier method
was used for survival analysis, and the log-rank test was used
to compare the 2 groups. The rate of hospitalization for
congestive heart failure (CHF) (12-month pre-enrollment
and post-discharge) was estimated and compared using a
Poisson regression model. A p value 0.05 was considered
significant.
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January 10, 2012:130–9 The EVEREST II HRS: 12-Month ResultsResults
We enrolled 78 patients who met all inclusion criteria in the
HRS. Thirty-six patients were included in the concurrent
comparator group.
Baseline demographics are listed in Table 1. The majority
of HRS patients were male and older than 75 years. All
patients had a history of CHF, and the majority had a
history of coronary artery disease. Additionally, more than
half the patients had previous cardiac surgery. Fifty-nine
percent of the HRS patients had functional MR, and 41%
had degenerative MR. Eighty-nine percent of patients were
in New York Heart Association (NYHA) functional class
III or IV. The predicted perioperative mortality rate based
on the protocol definition was 18.2% for the HRS group. Of
the 78 patients, 30 patients had an STS calculated score of
12% (mean calculated score: 7.1%) but a surgeon-
estimated mortality rate of at least 12% based on the
presence of prespecified baseline comorbidities. Using only
calculated STS scores for all 78 patients resulted in a mean
STS score of 14.2%. The baseline demographics of the
Baseline CharacteristicsTable 1 Baseline Characteristics
Characteristic
High
(
Age, yrs 76
75 yrs
Male
Comorbidities
5 comorbidities
Coronary artery disease
History of congestive heart failure
Chronic pulmonary disease
Moderate to severe renal disease
History of diabetes
History of cerebrovascular disease
History of peripheral vascular disease
Myocardial infarction
Atrial fibrillation
Previous cardiovascular surgery
Pacemaker or ICD implant
Percutaneous coronary intervention
NYHA functional class III or IV
LV ejection fraction 54
LV internal diameter, systole, cm* 3
MR etiology
Degenerative
Functional
Predicted surgical mortality rate (STS risk score
and/or surgeon estimated risk), %†
18
Predicted surgical mortality rate
(STS calculated risk score only), %‡
14
Values are mean  SD or %. *Measurements for concurrent compara
California, San Francisco. †STS risk calculated risk score if12% risk
a calculated STS score of 12%; 30 patients had a surgeon-estimate
STS score of 12%, and 12 patients had a surgeon-estimated risk sc
not used.ICD implantable cardioverter-defibrillator; LV left ventricular; MRmi
of Thoracic Surgeons.concurrent comparator group were similar, with a predicted
surgical mortality rate of 17.4%, based on either an STS
score of 12%, or a surgeon-estimated mortality rate if the
STS score 12%. The STS calculator score without sur-
geon estimates was 14.9% for the comparator group.
MitraClip procedure. In the HRS patients, 1 or 2 Mitra-
Clip MV repair devices were successfully placed in 75
patients (96%). MitraClip device placement was not suc-
cessful in 3 patients (4%). In 1 of these 3 patients, MR could
not be successfully reduced, and in 2 patients, the procedure
was aborted due to a transseptal complication and observa-
tion of an intracardiac thrombus after induction of general
anesthesia before initiating the MitraClip procedure (exclu-
sion). Sixty-two patients (79.5%) were implanted with a
device and achieved at least a 1-grade reduction in MR as
determined by the ECL, and 56 patients (71.8%) had
successful device placement and reduction in MR grade to
2 (Fig. 1).
30-day major adverse events. Six patients died within 30
days of the MitraClip procedure (central events committee
roup
8)
Concurrent Comparator Group
(n  36) p Value
.8 77.2 13.0 0.85
63.9 0.84
50.0 0.22
77.8 0.16
71.4 0.13
83.3 0.0007
33.3 0.95
31.4 0.36
41.7 0.999
22.2 0.62
22.9 0.61
36.4 0.10
52.8 0.41
72.2 0.40
13.9 0.02
30.6 0.53
83.9 0.20
3.7 55.2 18.1 0.82
.1 3.8 1.1 0.46
36.1 0.49
63.9
.0 17.4 7.4 0.42
.2 14.9 8.5 0.68
p performed by trained contract echocardiographer, not University of
on estimate based on pre-specified criteria. For HRS, 48 patients had
core. For concurrent comparator group, 24 patients had a calculated
S calculated risk score for all patients; surgeon estimated score was-Risk G
n  7
.7 9
61.5
62.8
88.5
84.2
100.0
34.6
23.1
41.0
17.9
18.2
55.8
61.6
62.8
35.1
38.5
89.7
.4 1
.9 1
41.0
59.0
.2 8
.2 8
tor grou
or surge
d risk s
ore. ‡STtral regurgitation; NYHA New York Heart Association; STS Society
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The EVEREST II HRS: 12-Month Results January 10, 2012:130–9adjudicated deaths as probably related to the procedure),
none of which occurred intraprocedurally, although 3 oc-
curred before hospital discharge. Events leading to death
included: 1) myocardial infarction secondary to diffuse
triple-vessel coronary artery disease (died on day 1); 2)
intraprocedural hemodynamic instability with subsequent
right heart failure (died on day 4); 3) transseptal complica-
tion that resulted in cardiac tamponade and ultimately acute
renal failure (died on day 9); 4) intraprocedural retroperito-
neal hematoma requiring vascular surgery resulting in acute
renal insufficiency, hypotension, and a stroke (died on day
11); 5) complications associated with prolonged anesthesia
and gastrointestinal bleeding (died on day 13); 6) CHF (no
device implanted; died on day 19). Overall 30-day mortality
rate in the HRS was 7.7%, significantly less than that
predicted for open-heart MV surgery (18.2% per protocol,
p  0.006; 14.2% per the STS calculator, p  0.06) in this
patient cohort. In the concurrent comparator group,
30-day mortality rate was 8.3% (3 of 36), which was not
different from the mortality rate in the HRS group (p 
NS). The cause of death in all 3 medically managed
comparator patients was cardiac.
Additional 30-day MAEs in surviving HRS patients
included a non–ST-segment elevation myocardial infarction
(asymptomatic post-procedure with a 3-fold increase in
creatine kinase, myocardial band) in a patient with a history
of myocardial infarction; a cerebrovascular accident with
persistent neurologic deficits 3 days post-procedure without
evidence of intracranial abnormalities on a computed to-
Figure 1 MR Reduction Through Discharge
MR  mitral regurgitation.mography scan; renal failure that responded to conservative atherapy; prolonged ventilation in a patient secondary to a
laryngeal tear from which the patient fully recovered. The
most common MAE was transfusion of 2 U of blood,
which occurred 22 times in 14 patients (17.9% of patients)
within 30 days of the procedure. The reasons for the 22
transfusion events were access site–related bleeding (n  9),
gastrointestinal bleeding (n  6), bleeding in an unspecified
ocation (n  3), and chronic anemia (n  4). Nonhierar-
hical MAEs through 30 days and 12 months are listed in
able 2.
MitraClip device embolization did not occur during the
tudy. One patient experienced MitraClip device attach-
ent to a single leaflet during the procedure and underwent
successful second MitraClip procedure 6 weeks later for
lacement of a second device.
2-Month effectiveness. The major effectiveness end-
oints for the HRS were freedom from death at 12 months,
reedom from death and MR 2 at 12 months, and
linical measures of benefit at 12 months in surviving
atients, defined as NYHA functional class, LV measure-
ents, SF-36 Health Survey quality of life, and rehospital-
zations for CHF.
Effectiveness of the MitraClip procedure, defined as MR
eduction to grade 2, and clinical measures of benefit at
2 months are presented in Table 3. Data for parameters
ith 30-day and 12-month follow-up, when available, are
lso presented in Table 3. Echocardiographic MR grade
mproved compared with baseline to 2 in 73% of
urviving patients at 30 days, and 78% of surviving patients
t 12 months; of these, 33% had MR grade 1 at 12
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January 10, 2012:130–9 The EVEREST II HRS: 12-Month Resultsmonths (Fig. 2A). NYHA functional class improved in the
vast majority of patients (Fig. 2B), as did quality of life. LV
end-systolic and end-diastolic volumes were reduced at 30
days, with further significant reductions observed at 12
months. Systolic and diastolic septal-lateral mitral annular
dimensions were significantly reduced from baseline to 12
months.
The number of patients with CHF hospitalizations de-
creased significantly from 42% (33 of 78) in the 12 months
before the MitraClip procedure to 16% (12 of 75) (p  0.02)
n the 12 months after discharge after the MitraClip proce-
ure, a 45% reduction. If readmission for CHF is imputed for
atients with cardiac death, then rehospitalization for CHF is
o longer significantly decreased after device treatment (p 
.09). Using only matched data in surviving patients, CHF
dmissions were reduced significantly (from 35 events in the
Clinical Results at Baseline and Follow-UpTable 3 Clinical Results at Baseline and Follow-Up
Clinical Parameter
Baseline
(n  78)
30 days
(n  72)
MR grade 2† 1.3 (1/78) 72.9 (51/7
NYHA functional class I/II‡ 10.2 (8/78) 73.2 (52/7
NYHA functional class III/IV‡ 89.8 (70/78) 26.8 (19/7
Quality of life, SF-36 score
Physical component, n  47 31.6 9.1 (73/78) 37.0 9.7 (6
Mental component, n  47 44.2 12.6 (73/78) 47.1 12.4
LV end-diastolic volume, ml 166 51 (78/78) 146 48 (7
LV end-systolic volume, ml 80 43 (78/78) 74 41 (7
Septal-lateral annular dimension, mm
Diastole 3.8 0.4 (74/78) 3.8 0.5 (6
Systole 3.2 0.4 (74/78) 3.2 0.4 (6
Rate of CHF hospitalizations
(per patient-year)§
0.65 (0.50–0.86) N/A
Values are % (n/N), mean SD (n/N), or hazard ratio (95% confidence interval). *All p values are b
efer to Figure 4 for matched LV volume data at baseline and 12 months for surviving patients.
Nonhierarchical Major Adverse EventsTable 2 Nonhierarchical Major Adverse Events
Pr
Description of Major Adverse Event* Patien
Death 7.7 (6/
Myocardial infarction 2.6 (2/
Reoperation for failed MV surgical repair or replacement 0.0 (0/
Urgent or emergent cardiovascular surgery for adverse event 0.0 (0/
Major stroke 2.6 (2/
Renal failure 3.8 (3/
Deep wound infection 0.0 (0/
Mechanical ventilation 48 h 2.6 (2/
GI complication requiring surgery 1.3 (1/
New onset of permanent AF 0.0 (0/
Septicemia 0.0 (0/
Transfusion of 2 U of blood 17.9 (14
Total† 26.9 (21
Patients are % (n/N). *Major adverse events were adjudicated by a central events committee. †S
number of patients in each category.
AF  atrial fibrillation; GI  gastrointestinal; MV  mitral valve.number of patients with NYHA functional class assessment in the follow-up period. §Poisson regression
CHF  congestive heart failure; CI  confidence interval; N/A  not available; SF-36  SF-36 Health Sear before treatment to 18 events in the year after device
reatment in 59 patients, p  0.034).
Freedom from death is illustrated by the Kaplan-Meier
urvival curve comparing patients in the HRS group with
he concurrent comparator group (Fig. 3). Importantly, no
urgery was performed in the HRS group through 1 year.
hirteen HRS patients died between 30 days and 12
onths; 6 were adjudicated as cardiac deaths (Table 4).
urvival at 1 year was significantly higher in the HRS group
ompared with the comparator group after the MitraClip
rocedure (76.4% vs. 55.3%, p  0.047).
mpact of etiology of regurgitation. Forty-six of the 78
RS patients had normal MV leaflet anatomy but had
alcoaptation of the leaflets secondary to leaflet restriction
nd LV dilation (FMR). The remaining 32 patients had
eaflet pathology consistent with degenerative disease
6 Months
(n  63)
12 Months
(n  56)
Baseline to 12-Month Change*
p Value
73.3 (44/60) 77.8 (42/54) 0.0001
80.3 (49/61) 74.1 (40/54) 0.0001
19.7 (12/61) 25.9 (14/54) 0.0001
N/A 36.5 10.6 (51) 0.01
N/A 49.2 12.0 (51) 0.06
141 44.5 (60) 140 43 (54) 0.001
71.4 34.8 (60) 72 36 (54) 0.001
3.7 0.4 (57) 3.6 0.3 (52) 0.0001
3.1 0.4 (57) 3.0 0.4 (52) 0.0008
N/A 0.36 (0.24–0.54) 0.018
n data for surviving patients with baseline and 12-month follow-up, except for CHF hospitalization.
minator indicates number of patients with echocardiographic follow-up. ‡Denominator indicates
re Through 30 Days Procedure Through 12 Months
No. of Events Patients No. of Events
6 24.4 (19/78) 19
2 5.1 (4/78) 5
0 0.0 (0/78) 0
0 0.0 (0/78) 0
2 2.6 (2/78) 2
3 6.4 (5/78) 5
0 0.0 (0/78) 0
2 2.6 (2/78) 2
1 3.8 (3/78) 3
0 0.0 (0/78) 0
0 3.8 (3/78) 3
22 24.4 (19/78) 31
38 42.3 (33/78) 69
tients experienced 1 event; hence, the total number of patients is not equal to the sum of the0)
1)
1)
4)
(64)
0)
0)
4)
4)
ased o
†Denoocedu
ts
78)
78)
78)
78)
78)
78)
78)
78)
78)
78)
78)
/78)
/78)
ome pamodel.
urvey; other abbreviations as in Table 1.
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7 of 32 (22%) DMR patients died. At 1 year, 34 of the
FMR patients and 20 of the DMR patients had matched
baseline and 12-month follow-up data available for com-
parison. At 1 year, 79% of the FMR and 75% of the DMR
patients had sustained MR reduction with 2 MR by
ECL determination. Twenty-five of 34 FMR patients
(74%) and 15 of 20 DMR patients (75%) had improvement
to NYHA functional class I/II at 1 year. Only 1 patient was
in NYHA functional class IV at 1 year compared with 16 at
baseline in the entire cohort. Eighty percent of FMR
patients and 89% of DMR patients improved by1 NYHA
functional class at 1 year. Improvement in end-diastolic
volume and end-systolic volume were significant in the
FMR patients (Fig. 4). Diastolic and systolic septal-lateral
annular dimensions also decreased significantly at 1 year in
the FMR group with a trend for a decrease in the DMR
Figure 2 Changes in Matched MR Severity and
Functional Class From Baseline to 12 Months
(A) Change in mitral regurgitation (MR) severity from baseline to 12 months
(12-month matched data). (B) Change in New York Heart Association (NYHA)
functional class from baseline to 12 months (12-month matched data).group.Discussion
Clinical experience with the MitraClip procedure began in
2004 (15). Encouraging initial results were reported by
Feldman et al. (8,10) in 2005 and 2009. Results of the
randomized, controlled trial comparing the MitraClip de-
vice with MV surgery were reported by Feldman et al. in
2011 (11), with 78% of randomized patients remaining free
of MV surgery at 2 years. However, these cohorts were
limited to patients deemed acceptable surgical candidates
with relatively preserved LV function.
The present study specifically selected symptomatic pa-
tients with moderate to severe or severe MR at high risk of
MV surgery. Results demonstrate that these patients who
were not considered to be suitable candidates for surgery can
be successfully treated with the MitraClip System to reduce
the degree of MR with procedural mortality rate less than
that predicted for surgical treatment and 30-day mortality
rate not different from that of a concurrent comparator
group receiving standard care (Fig. 3).
Mortality at 30 days in the HRS was lower than the
predicted surgical mortality rate for this group, although
there were 6 procedure-related deaths (7.7%). Although
there is no high-risk, medically treated historical control
group that matches the HRS cohort available for compari-
son, survival was similar to that of a concurrent comparator
group with significant MR and comparable baseline comor-
bidities. These data and an acceptable rate of MAEs suggest
that placement of the MitraClip device is relatively safe and
feasible in these high-risk patients. Additionally, 1-year
mortality rate in the HRS was reduced compared with the
concurrent comparator group. The authors believe that the
potential survival benefit observed in this study merits
further investigation and may be clinically important
(16,17).
At 1-year follow-up of surviving patients with matched
data, the MitraClip procedure resulted in an improvement
in the severity of MR, a decrease in NYHA functional class,
a decrease in LV end-systolic and end-diastolic volumes,
and a decrease in mitral annular dimensions in both FMR
and DMR patients. The number of admissions for CHF
was also significantly reduced compared with the year before
MitraClip therapy in surviving patients with matched data.
However, the impact of these comparisons is limited be-
cause no matched data are available for patients who did not
survive 12 months.
The observed reductions in LV diastolic and systolic
volumes at 30 days and 12 months for high surgical risk
patients in this study as well as the reduction in mitral
annular dimensions suggest that MitraClip therapy results
in early reverse of LV remodeling. Furthermore, paired LV
echocardiographic parameters at 12 months in FMR and
DMR patient subsets demonstrate that reverse LV remod-
eling occurs in both patient subsets with significant MR
regardless of underlying pathology. These objective im-
provements in LV function, in addition to the subjective
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the patients, suggest that percutaneous reduction of MR
with the MitraClip device results in significant clinical
benefit.
The stabilization of mitral annular dimensions observed
after leaflet repair with the MitraClip device is encouraging
because concerns have been raised that MitraClip leaflet
repair without concomitant annuloplasty might result in
progressive annular dilation. Longer follow-up is needed to
confirm whether these initially favorable findings persist.
Figure 3 Kaplan-Meier Curve for Survival: All Patients
CCG  concurrent comparator group; HRS  High Risk Study.
HRS Patient Deaths Through 12 MonthsTable 4 HRS Patient Deaths Through 12 Months
Patient # Age, yrs
STS-Predicted
Mortality, %
No. of MitraClips
Implanted
MR Grad
Post-Mitr
1* 65 13.5 2
2* 75 14.1 1
3* 84 10.2 0
4 78 16.3 2
5 90 15.2 1
6 89 18.3 0
7 77 10.4 1
8 90 14.3 2
9 66 8.1 1
10 76 7.2 2
11 77 4.3 2
12 87 18.2 0
13 75 16.5 2
14 87 36.1 1
15 70 12.7 2
16 78 12.5 1
17 80 13.0 1
18 88 13.2 1
19 77 10.9 1
*Patients died before discharge fromMitraClip procedure. †Patient withdrew from study before dea
so no cause of death is available.
MR  mitral regurgitation; NA  not assessed; STS  Society of Thoracic Surgeons.Study limitations. Several limitations of the present study
should be considered. First, the comparator group was
recruited retrospectively, the patient number is limited,
transesophageal echocardiograms were not available for
review in all patients, and several of the patients included
did not have appropriate anatomic criteria for MitraClip
placement. Transthoracic echocardiograms determining pa-
tient eligibility for the comparator group were read by the
site and contract echocardiographers; however, they were
not reviewed by the ECL. These differences could poten-
ischarge
Procedure
Time to Death
Post-MitraClip Procedure,
days
Central Events Committee
Adjudicated Cause of Death
(Cardiac- or Noncardiac-Related)
1 Cardiac
4 Cardiac
9 Cardiac
11 Cardiac
13 Cardiac
19 Cardiac
44 Cardiac
63 Cardiac
67 Cardiac
97 Noncardiac
115 Noncardiac
128 Noncardiac
160 Noncardiac
170 Noncardiac
190 Cardiac
244 Noncardiac
296 Cardiac
307 Not done†
329 Cardiac
vent was not adjudicated by the central events committee. Death identified in newspaper obituary,e Pre-D
aClip
4
NA
4
2
4
4
4
3
3
2
2
NA
1
2
2
1
2
3
1
th, so e
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paring the HRS patients with the comparator group. De-
spite these limitations, the comparator group did all have
symptomatic 3 to 4 MR by site and contract echocardio-
graphic assessment and had comorbidities and STS scores
similar to those of the HRS group. The authors believe that
following this group for vital status adds important insight
into the limited survival expected in such ill patients treated
by the current standard of care. However, direct comparison
between HRS and concurrent comparator groups should be
done with caution.
A second concern is that 12-month echocardiographic
and functional data were obtained and reported for surviving
patients only, and no imputation for deceased patients’ data
was performed. Thus, the matched data reported may
represent an overestimation of the true benefit provided by
MitraClip placement.
Conclusions
The data from this HRS suggest a role for the MitraClip
device in treating symptomatic patients with 3 to 4MR who
are at high risk of mortality with MV surgery. MitraClip device
placement in this selected high-risk group is feasible, effective
in reducing symptoms and improving clinical status, and
relatively safe in patients who otherwise have no safe option to
reduce MR. Favorable LV remodeling demonstrates that the
degree of reduction in MR obtained with the MitraClip device
is hemodynamically important. Long-term follow-up is ongo-
ing and needed to confirm whether the benefits observed at 12
Figure 4 Left Ventricular End-Diastolic and End-Systolic Volume
Baseline to 12 months (matched data, mean  SE). LVEDV  left ventricular end
MR  mitral regurgitation.months are sustained.Reprint requests and correspondence: Dr. Patrick L. Whitlow, De-
partment of Cardiovascular Medicine, J2-3, Cleveland Clinic, 9500
Euclid Avenue, Cleveland, Ohio 44195. E-mail: whitlop@ccf.org.
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